 My name is Martin Gutierrez and the Co-Chief of the Thoracic Oncology and the Director of the Phase 1 Program at Hackensack University Medical Center. I usually treat patients with thoracic malignancies, so lung cancer, mesothelioma, thymide, carcinoma, as well as GI malignancies, so esophageal cancer, pancreatic, hepatocellular colon cancer. We used to treat lung cancer only with chemotherapy until the early 2000s, then target therapy came on board and then between 2011 and 2015 immunotherapy surfaced into the thoracic oncology and clearly made a major impact prolonging the survival to up to three years, median survival is even longer than that and there is data coming out of survival even up to 15% at four or five years, which we never saw before. It has clearly proved that has an impact in solitumors in the vast, in the grand majority of them, but nevertheless we still not curing 100% of those patients, there is still a large gap to improve and that is what the Phase 1 Program offered to the patients and it's a collaboration between multiple sponsors, pharmaceutical companies, physicians and clearly the patients who are altruistic and decide to go into these clinical trials. In the Phase 1 Program we have actually a wide variety, we run approximately 40 different clinical trials, focus in immunotherapy heavily, but also in targeted therapies and in cell technologies today such as NK cells and CAR T cells. CAR T cell therapy is a new technology, it's an evolving technology, for example right now we have a CAR T cells for her to positive diseases, so breast cancer, gastrics and the colon cancer patients who had her to expressive tumors. What it means is we have a harvest of the, we call it ferruses of their white cells and they get engineered to recognize the target, in this case her too. Those cells are given back to the patient with the idea that it will target specifically the cancer. The idea that we can use an engineer T cells that can recognize specific targets on those cell tumors and be able to induce a response, produce a huge degree of excitement. When patients come to JTCC they are getting a centralized care, constantly providing new options of care for them in this fight against cancer.